New Research Released on Precision Therapeutics Inc. (AIPT-NASDAQ)

Posted by Karen Goldfarb

July 9, 2018 at 12:34 PM

An Executive Informational Overview (EIO) is now available on medical technology company, Precision Therapeutics Inc. (AIPT-NASDAQ). The EIO is a 70-page report detailing Precision Therapeutics' business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

VIEW REPORT

Read More

Topics: precision therapeutics, aipt, precision medicine, artificial intelligence (AI), medical fluid waste collection, precision oncology, genomic, bioinformatics, D-CHIP™, TumorGenesis, GLG Pharma, STREAMWAY System, Skyline Medical, Helomics® Corporation, personalized medicine

March 2018 Update Issued on GeoVax Labs, Inc. (GOVX-OTC)

Posted by Karen Goldfarb

March 1, 2018 at 1:51 PM

Crystal Research Associates has issued a 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Download Update

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

Aeterna Zentaris’ Marketing Authorization Application for Macrilen™ (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency

Posted by Karen Goldfarb

November 28, 2017 at 10:14 AM

Aeterna Zentaris Inc. (AEZS-NASDAQ) announced the Marketing Authorization Application (MAA) for the use of Macrilen™ (macimorelin) to evaluate adult growth hormone deficiency (AGHD) has been accepted by the European Medicines Agency (EMA) for regulatory review. Aeterna seeks to become the future for AGHD management and for Macrilen to emerge as the drug that endocrinologists and their staff use as the preferred test for their patients.

Macrilen™ is the first innovation in adult GHD testing in over 50 years. Aeterna believes that the drug could eliminate the testing burden of the current standard, which requires physician-supervised administration and up to double digital patient blood draws over several hours. Macrilen™, an orally available ghrelin agonist, stimulates the secretion of growth hormone from the pituitary gland. Stimulated growth hormone levels are measured in blood samples after oral administration of Macrilen™ for the assessment of growth hormone deficiency (GHD).

AGHD affects roughly 75,000 adults across the U.S., Canada, and Europe. Growth hormone not only plays an important role in growth from childhood to adulthood, but also helps promote a hormonally-balanced health status. AGHD mostly results from damage to the pituitary gland, and is typically characterized by a reduction in bone mineral density, lean body mass, exercise capacity, and overall quality of life, as well presents a higher risk for cardiovascular issues.

On March 7, 2017, the Pediatric Committee of the EMA agreed to the Company’s Pediatric Investigation Plan (PIP) for Macrilen™, a prerequisite for filing an MAA for any new medicinal product in Europe. The EMA also agreed that the company may defer conducting the PIP until after it filed a MAA for the use of Macrilen™ in AGHD. The start of the EMA review procedure for the MAA has now been confirmed by EMA as November 23, 2017. 

Read More

Topics: AEZS, Macrilen

New Research Released on ZapGo Ltd (closely held)

Posted by Karen Goldfarb

November 8, 2017 at 10:05 AM

An Executive Informational Overview (EIO) is now available on technology company, ZapGo Ltd (closely held). The EIO is a 68-page report detailing ZapGo's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Download ZapGo Report

Read More

Topics: technology, batteries, energy storage device, Zap&Go, Gen 4 technology, eletric cars, Carbon-Ion™, C-Ion®, ZapGo Ltd, proprietary Gen 3 technology, mobile phones, laptop computers, cordless power tools

October 2017 Update Issued on GeoVax Labs, Inc. (GOVX-OTC)

Posted by Karen Goldfarb

October 18, 2017 at 3:50 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC). The Update details GeoVax's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. As well, the Update follows GeoVax's development, strategic relationships, and market opportunities. It is available for download below.

Download Update 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

NDA for Aeterna Zentaris' (AEZS) Macrilen™ Granted December 30, 2017 PDUFA Date

Posted by Karen Goldfarb

July 19, 2017 at 11:23 AM

Aeterna Zentaris Inc. (AEZS-NASDAQ) announced that it has been notified by the U.S. Food and Drug Administration (FDA), that the Company’s New Drug Application (NDA) seeking approval of Macrilen™ (macimorelin) for the evaluation of growth hormone deficiency in adults (AGHD) has been accepted as a complete response to the FDA’s November 5, 2014 Complete Response Letter and granted a PDUFA date of December 30, 2017. 

The Company remains confident that the FDA will approve its NDA and, accordingly, is moving forward with preparations to launch the product in the first quarter of 2018. In other news, the Company also announced that Mr. Kenneth Newport is no longer a member of the Board of Directors effective as of July 12, 2017.

Macimorelin, a ghrelin agonist, is an orally-active small molecule that stimulates the secretion of growth hormone. The product candidate has been granted orphan drug designation by the FDA for diagnosis of AGHD. Aeterna owns the worldwide rights to this patented compound and has significant patent protection remaining. The Company’s U.S. composition of matter patent expires in 2022 and its U.S. utility patent runs through 2027. Aeterna proposes, subject to FDA approval, to market macimorelin under the tradename Macrilen™.

AGHD affects roughly 75,000 adults across the U.S., Canada and Europe. Growth hormone not only plays an important role in growth from childhood to adulthood, but also helps promote a hormonally-balanced health status. AGHD mostly results from damage to the pituitary gland. It is usually characterized by a reduction in bone mineral density, lean body mass, exercise capacity, and overall quality of life as well as an increase of cardiovascular risks. 

Read More

Topics: AEZS, Macrilen

GeoVax Labs. (GOVX-OTC) Reports Promising Results for Lassa Fever Vaccine

Posted by Karen Goldfarb

July 11, 2017 at 4:27 PM

Promising Results Reported for GeoVax's Lassa Fever Vaccine

GeoVax announced today a significant step forward in developing its vaccine candidate for protection against Lassa hemorrhagic fever virus (LASV). Efficacy testing in a murine challenge model (using a LASV reassortant) showed a single dose of the candidate vaccine, GEO-LM01, provided 100% protection to mice infected with a lethal dose of the challenge virus.

During testing, mice were given a single-dose vaccination of GEO-LM01 into muscle tissue, then infected with 1000 Plaque Forming Unit of the challenge virus by intracranial inoculation. All vaccinated mice survived while all unvaccinated mice died within one week of infection. Vaccinated animals produced a strong T cell immune response against LASV at 10 days post vaccination. The study was conducted at the Institute of Human Virology at the University of Maryland School of Medicine in Baltimore, with a repeat of the study confirming the findings.

A member of the Arenaviridae virus family, LASV causes severe and often fatal hemorrhagic illnesses in an overlapping region with Ebola virus (EBOV). Compared to the unpredictable epidemics of filoviruses such as EBOV, LASV is endemic in West Africa with an annual incidence of over 300,000, and leading to 5,000 to 10,000 deaths.

New study data suggests that the annual number of LASV cases may actually be meaningfully higher, with 3 million infections and 67,000 deaths (making upwards of 200 million individuals at risk). There are no treatments or vaccines available today to stem LASV epidemics, even though LASV kills more people in one year than the EBOV did in the last 41 years after its first epidemic in 1976 in West Africa.

GeoVax's GEO-LM01 uses the Company's proven MVA-VLP vaccine platform, which has been shown to be safe and to induce durable antibody and T cell responses in multiple human clinical trials for GeoVax’s prophylactic HIV vaccine. Using the same platform, a single dose of GeoVax’s Ebola vaccine has been shown to protect 100% of rhesus monkeys against death.

GeoVax is also developing vaccines against Sudan virus (SUDV) and Marburg virus (MARV), two other lethal filoviruses for which no effective vaccine currently exists. In addition to developing the four individual vaccines (EBOV, LASV, SUDV, MARV), the Company’s seeks to combine the vaccines into a single tetravalent vaccine to provide broad protection for individuals at-risk for these viruses.

Lassa fever has a greater human impact than any other hemorrhagic fever virus, except for dengue fever, and despite this clear need, no vaccine has yet entered human clinical trials. GeoVax is now ready for advanced preclinical testing, which could lead to initiation of human clinical trials.

For more information on GeoVax, please refer to our Executive Informational Overview (EIO), issued on June 15, 2017. This EIO is a 80-page report detailing GeoVax's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Download GeoVax Report 

 

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv

New Research Released on GeoVax Labs, Inc. (GOVX-OTC)

Posted by Karen Goldfarb

June 19, 2017 at 4:55 PM

An Executive Informational Overview (EIO) is now available on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC). The EIO is a 80-page report detailing GeoVax's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Download GeoVax Report 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

May 2017 Update Released on Aeterna Zentaris (AEZS)

Posted by Karen Goldfarb

May 15, 2017 at 2:59 PM

Crystal Research Associates has released an 11-page Quarterly Update on specialty biopharmaceutical company, Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX). The Update specifically details Aeterna's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. 

  Download Update

Read More

Topics: AEZS

April 2017 Update Released on Aeterna Zentaris (AEZS)

Posted by Karen Goldfarb

April 5, 2017 at 1:33 PM

Crystal Research Associates has released an 11-page Quarterly Update on specialty biopharmaceutical company, Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX). The Update specifically details Aeterna's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. 

 

 Download Update

Read More

Topics: AEZS

New Research Released on Avivagen Inc. (VIV-TSX.V)

Posted by Karen Goldfarb

March 7, 2017 at 12:41 PM

An Executive Informational Overview (EIO) is now available on pharmaceutical company, Avivagen Inc. (VIV-TSX.V). The EIO is a 56-page report detailing Avivagen's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Download Avivagen Report

Read More

February 2017 Update Released on Aeterna Zentaris (AEZS)

Posted by Karen Goldfarb

February 27, 2017 at 2:56 PM


Crystal Research Associates has released a 10-page Quarterly Update on specialty biopharmaceutical company, Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX). The Update specifically details Aeterna's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. 

Download Update

 

Read More

Topics: AEZS

MagneGas Signs Definitive Agreements for $2.65 Million Equipment Sale to German Company

Posted by Karen Goldfarb

January 5, 2017 at 10:31 AM


As Largest Single Sale in MagneGas History, MagneGas Signs Definitive Agreements for $2.65 mm of Equipment to German Company

MagneGas announced that it has entered into its largest equipment sale to date with the signing of definitive agreements to manufacture and deliver certain equipment and supplies to a German-based company. Under the terms of this Agreement, for which MagneGas will receive $2.65 million, MagneGas will supply MagnesGas2® fuel and cylinders and manufacture and deliver (1) A 300KW stationary Gasification system; (2) A 100KW mobile Sterilization system; (3) 250 cylinders full of MagneGas2®; and (4) 50 MagneGas regulators.  

A deposit of $25,000 has been received, with progress payments totaling $2.625 million to be paid over the course of the manufacturing and delivery of the various systems.  The first payment of $1.35 million is due in 90 days with progress payments due thereafter, with set construction and delivery milestones. The German company has stated that it may be interested in negotiating to purchase several additional systems for multiple markets.  

The German company expects to initially utilize the Gasification system to produce MagneGas2® fuel to sell into the German market with the potential for other markets coming online in the future.  The Sterilization system is expected be used for demonstrations and small service contracts with the goal of entering the agriculture and municipal wastewater treatment markets in Germany.

 Research Available on MagenGas

Our most recently published Executive Informational Overview (EIO) on MageGas Corporation is available below for download. This a 68-page report details MagneGas' business, novel technology and product development, market opportunities, competition, financials, risks, and more.

Read More

Topics: magnegas

Sir Gregory Winter Appointed as Interim Chair of Biosceptre Int'l

Posted by Karen Goldfarb

December 16, 2016 at 3:20 PM

Announces Appointment of Independent Director Sir Gregory Winter as Chair of the Board of Directors

Biosceptre announced that has appointed Sir Gregory Winter as Chair of the Biosceptre Board of Directors. Sir Gregory has led the Scientific Advisory Board of Biosceptre for over 4 years and joined the Board of Directors as a non-executive director in May 2016. Sir Gregory Winter is Master of Trinity College Cambridge and was a past member of the Medical Research Council’s Laboratory of Molecular Biology (LMB), serving as both a Head of Division and as Deputy (and Acting) Director.

Sir Gregory has developed technology to make humanized antibodies and human antibodies in bacteria. A number today's available therapeutic antibodies were developed using methods devised by Sir Gregory. Sir Gregory has unique biotechnology industry experience, being a Founder and Director of Cambridge Antibody Technology (acquired by AstraZeneca), of Domantis (acquired by GlaxoSmithkline) and currently of Bicycle Therapeutics Limited.

Sir Gregory was elected a Fellow of the Royal Society (FRS) in 1990 and awarded the Royal Medal by the society in 2011 for his pioneering work in protein engineering and therapeutic monoclonal antibodies, and his contributions as an inventor and entrepreneur. He has also won several international awards including the King Faisal International Prize for Medicine, the Cancer Research Institute William B. Coley Award and the Canada Gairdner International Award. Sir Gregory was appointed Knight Bachelor in 2004.

Research Available on Biosceptre

Our most recently published Executive Informational Overview (EIO) on Biosceptre International Ltd is available below for download. This a 52-page report details Biosceptre's business, novel technology and product development, market opportunities, competition, financials, risks, and more.

Read More

Topics: Biosceptre

New Research Released on Hemispherx Biopharma $HEB

Posted by Laura Swartz

November 28, 2016 at 8:51 PM

An Executive Informational Overview (EIO) is now available on specialty pharmaceutical company, Hemispherx Biopharma, Inc. (HEB-NYSE). The EIO is a 60-page report detailing Hemispherx's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Read More

Topics: HEB

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic